Welcome to our dedicated page for Moleculin Biotec SEC filings (Ticker: MBRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Moleculin Biotech, Inc. filings document regulatory disclosures for a Delaware clinical-stage pharmaceutical company focused on drug development and commercialization. Recent Form 8-K reports cover Regulation FD releases, investor presentations, financial results, clinical and preclinical updates for Annamycin, and intellectual-property matters involving liposomal Annamycin.
The filing record also includes capital-structure and governance disclosures tied to warrant exercise inducement arrangements, warrant-related share issuance, and stockholder voting matters. Definitive proxy materials and voting results describe special-meeting proposals, including Nasdaq-related approval for warrant shares and charter-related governance items, while exhibit filings attach press releases, presentation materials, and other public-company disclosures.
Moleculin Biotech reported positive preliminary results from the first 45 patients in Part A of its pivotal Phase 2/3 MIRACLE trial in relapsed or refractory acute myeloid leukemia. On a full intent-to-treat basis, both Annamycin arms showed higher remission rates after a single treatment cycle compared with the HiDAC control arm.
The 190 mg/m² and 230 mg/m² Annamycin plus HiDAC arms achieved complete remission rates of 43% and 36%, versus 12% for control. Composite complete remission reached 50% and 57% in the Annamycin arms versus 29% for control. An independent data monitoring committee saw a strong numeric efficacy trend favoring Annamycin and recommended continuing the trial without dropping either dose.
Enrollment in Part A has reached 67 of 90 planned subjects, and efficacy data from Part A are expected to carry into the pivotal Part B analysis. The company notes that these efficacy results are interim, based on a small sample size and not yet statistically significant, and it will need significant additional financing, with no current commitments, to complete its clinical plans.
Moleculin Biotech, Inc. reported that, after filing its quarterly report for the period ended March 31, 2026, investors exercised warrants to purchase 1,361,500 shares of common stock, generating gross proceeds of approximately $2.7 million for the company. As of June 29, 2026, Moleculin Biotech had 7,065,000 shares of common stock outstanding. The company also made available an updated corporate presentation, furnished as Exhibit 99.1.
Moleculin Biotech, Inc. Chief Science Officer Donald H. Picker reported routine equity compensation activity involving restricted stock units (RSUs). On June 20 and June 22, he exercised RSUs to acquire a total of 115 shares of common stock at a conversion price of $0.00 per share.
Across both dates, 34 common shares were withheld at prices of $2.88 and $3.12 per share to cover tax obligations upon RSU vesting, a non‑market disposition. Following these transactions, he directly holds 774 shares of common stock and 19,596 RSUs that convert into common stock on a one‑for‑one basis.
Moleculin Biotech, Inc. CEO and President Walter V. Klemp reported routine equity compensation activity involving restricted stock units and related tax withholding. On June 20 and June 22, restricted stock units converted into a total of 510 shares of common stock at a conversion price of $0.00 per share. To cover tax obligations on these vestings, a total of 125 common shares were disposed of via tax-withholding transactions, rather than open-market sales. After these transactions, Klemp directly held 31,007 shares of common stock and continued to hold a substantial equity position through 326,336 restricted stock units, as well as 250,002 shares of common stock underlying Series E warrants.
Moleculin Biotech, Inc. Chief Financial Officer Jonathan P. Foster reported routine equity compensation activity involving restricted stock units and related tax withholding. On June 20 and June 22, 2026, restricted stock units converted into a total of 283 shares of common stock at a conversion price of $0.00 per share.
To cover tax obligations on these vestings, 72 shares of common stock were disposed of at prices of $2.88 and $3.12 per share through tax-withholding dispositions, not open-market sales. Following these transactions, Foster directly holds 12,381 shares of common stock and 147,718 derivative securities, which include 100,003 shares of common stock underlying Series E warrants.
Moleculin Biotech furnished an update on independent market research evaluating its lead drug candidate Annamycin for relapsed/refractory acute myeloid leukemia. Surveyed oncologists reported an average likelihood-to-prescribe score of 6 out of 7, citing deep remissions, transplant-bridging potential, biomarker-agnostic use and reduced cardiotoxicity.
Interviews with hospital administrators and insurers indicated that payers view Annamycin as addressing a significant unmet need, with a potentially meaningful value proposition. Moleculin highlighted that it is a Phase 3 clinical stage company and is advancing the MIRACLE pivotal Phase 2b/3 trial of AnnAraC in R/R AML, while emphasizing that the research sample was small and qualitative and that it will require significant additional financing to conduct its clinical trials.
Moleculin Biotech filed an 8-K to highlight new clinical data on its lead drug candidate Annamycin presented at the 2026 ASCO meeting. A pooled analysis of 90 patients with acute myeloid leukemia and soft tissue sarcoma found no detectable cardiotoxicity, even at cumulative doses far above traditional anthracycline limits.
The analysis used paired left ventricular ejection fraction assessments in 78 patients and was independently reviewed by Cleveland Clinic cardiology specialists. Moleculin views these safety data as strengthening support for its pivotal Phase 2b/3 MIRACLE trial of AnnAraC (Annamycin plus cytarabine) in relapsed or refractory AML, with unblinding of the first 45 patients expected in June 2026.
Moleculin Biotech, Inc. furnished a new investor presentation as part of a current report. The company is using this May 2026 corporate presentation, attached as Exhibit 99.1, for its website and investor communications. The material is provided under a Regulation FD disclosure item and is expressly treated as “furnished,” not “filed,” which means it is not automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced later.
Moleculin Biotech, Inc. furnished a press release announcing that pooled cardiac safety data for its lead drug candidate Annamycin were accepted for poster presentation at the 2026 ASCO Annual Meeting. The pooled analysis covered 90 patients with acute myeloid leukemia and soft tissue sarcoma treated across five completed clinical trials.
The abstract reports a median cumulative L-Annamycin dose of 660 mg/m2, with most patients receiving doses above conventional lifetime anthracycline limits, yet showing no statistically significant change in left ventricular ejection fraction from baseline to final assessment and no evidence of drug-induced cardiotoxicity on independent review. Previously reported Phase 1b/2 data in relapsed or refractory AML showed a 50% complete remission rate, 60% composite complete remission rate, and median overall survival of 12.39 months, supporting the company’s ongoing pivotal Phase 2b/3 MIRACLE trial of Annamycin plus cytarabine.
Moleculin Biotech reported first quarter 2026 results and highlighted progress in its pivotal MIRACLE trial for relapsed or refractory acute myeloid leukemia. Early blinded data show a 40% composite complete remission rate in this difficult-to-treat population. The first interim unblinding is expected in June 2026 after enrollment of 45 subjects, with the 90th subject targeted for Q3 2026.
For the quarter ended March 31, 2026, Moleculin had no revenue and reported research and development expenses of $5.4 million, up from $3.4 million a year earlier, mainly due to MIRACLE trial costs. General and administrative expenses were stable at about $2.5 million. The company recorded a net loss of $12.8 million versus $5.9 million in 2025, influenced by warrant-related fair value charges and a warrant deemed dividend, bringing net loss available to common stockholders to $14.6 million, or $3.54 per share.
Cash and cash equivalents were $10.3 million as of March 31, 2026. Management believes existing cash, together with recent financing proceeds, will fund planned operations into the third quarter of 2026, and notes that significant additional financing will be required to conduct the described clinical trials.